RE:Enhanced Provisional Patent Globally 🤑This was a good NR to bring back up. The patent is in place as are the Trademarks.
This is a $10 in the making, but going global while maintaining a small float could make this a $20 - $30 company. All for 0.42 cents right now!!! Those who can't see the forest from the trees will not be able to comprehend this.
DirkDiggIer1 wrote: Lifestyle Delivery Systems Inc. (CSE: LDS), (OTCQB: LDSYF), (XETR:LD6) ("LDS" or the "Company") announces the filing of an enhanced provisional patent for the CannaStripsTM technology and two additional applications for CannaStrips trademark protection in the United Kingdom and European Union to complement the Company's current Canadian trademark application.
The new provisional patent filed by Dr. Sanderson, the Company's Chief Science Officer and the licensor of the CannaStripsTM technology, adds additional enhanced capabilities to the current CannaStripsTM formula, which will be implemented into the 2018 CannaStripsTM product line. The new trademark applications are intended as an anticipatory action to protect the CannaStripsTM oral strips brand in geographical territories where the Company may have future plans for distribution. The Canadian trademark filing was made back in April 2017, as part of the structural predevelopment plans for possible future product licensing and distribution collaboration or partnership regarding CannaStripsTM technology in Canada. The Company has made its interest to collaborate on clinical trials in Canada known to a number of Canadian licensed producers ("LP"). Should the Company come to an agreement with a Canadian LP for sponsorship of Canadian clinical trials and subsequently have those trials result in an approval from Health Canada for the CannaStripsTM technology for use in Canada, the Company would focus on a license agreement to introduce CannaStripsTM into the Canadian market. LDS CEO, Brad Eckenweiler, stated, "We strongly believe that the CannaStripsTM delivery system is so unique that with clinical trials from a recognized health organization to substantiate the efficacy of the technology it would have to be at the top of the list of preferred delivery solutions anywhere in the world."
The Company will continue to pursue a collaborative effort for clinical trials with the intent on accomplishing commencement of those clinical trials in the first quarter of 2018.
It’s all coming together now ! GLTA